Genetic Therapy Approaches for Ornithine Transcarbamylase Deficiency.

Genetic Therapy Approaches for Ornithine Transcarbamylase Deficiency.
复制标题

DOI:
10.3390/biomedicines11082227
复制
发表时间:
2023-08-08
期刊:
影响因子:
4.7
通讯作者:
--
中科院分区:
工程技术3区
文献类型:
--
作者:

文献摘要

参考文献

相似文献

鸟氨酸转氨酶缺乏症(OTCD)是最常见的尿素循环障碍,有很高的未得到满足的需求,因为目前的饮食和药物治疗可能不足以预防高氨血症发作,这可能导致死亡或神经后遗症。到目前为止,肝移植是唯一的治疗选择,但由于供体短缺、需要终身免疫抑制和技术挑战,还没有得到广泛的应用。最近显示出巨大前景的一个研究领域是基因治疗,而OTCD已经成为不同基因治疗模式的必要候选,包括AAV基因添加、信使核糖核酸治疗和基因组编辑。本文将首先总结临床翻译的主要步骤,突出每种基因治疗方法的优点和挑战,然后重点介绍目前的临床试验,最后概述OTCD基因治疗的未来发展方向。
Ornithine transcarbamylase deficiency (OTCD) is the most common urea cycle disorder with high unmet needs, as current dietary and medical treatments may not be sufficient to prevent hyperammonemic episodes, which can cause death or neurological sequelae. To date, liver transplantation is the only curative choice but is not widely available due to donor shortage, the need for life-long immunosuppression and technical challenges. A field of research that has shown a great deal of promise recently is gene therapy, and OTCD has been an essential candidate for different gene therapy modalities, including AAV gene addition, mRNA therapy and genome editing. This review will first summarise the main steps towards clinical translation, highlighting the benefits and challenges of each gene therapy approach, then focus on current clinical trials and finally outline future directions for the development of gene therapy for OTCD.
DOI: 10.1186/s13023-015-0266-1
发表时间: 2015-05-10
影响因子: 3.7
作者:
Brassier A;Gobin S;Arnoux JB;Valayannopoulos V;Habarou F;Kossorotoff M;Servais A;Barbier V;Dubois S;Touati G;Barouki R;Lesage F;Dupic L;Bonnefont JP;Ottolenghi C;De Lonlay P
通讯作者: De Lonlay P
DOI: 10.1089/hgtb.2016.039
发表时间: 2016-12-01
影响因子: --
作者:
Bell, Peter;Wang, Lili;Wilson, James M.
通讯作者: Wilson, James M.
DOI: 10.1038/mt.2011.32
发表时间: 2011-05-01
期刊: MOLECULAR THERAPY
影响因子: 12.4
作者:
Cunningham, Sharon C.;Kok, Cindy Y.;Alexander, Ian E.
通讯作者: Alexander, Ian E.
DOI: 10.1038/nature13864
发表时间: 2015-01-15
期刊: NATURE
影响因子: 64.8
作者:
Barzel, A.;Paulk, N. K.;Shi, Y.;Huang, Y.;Chu, K.;Zhang, F.;Valdmanis, P. N.;Spector, L. P.;Porteus, M. H.;Gaensler, K. M.;Kay, M. A.
通讯作者: Kay, M. A.
DOI: 10.1016/j.omtm.2022.10.006
发表时间: 2022-12-08
期刊: MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT
影响因子: --
作者:
Deplazes, Sereina;Schlegel, Andrea;Song, Zhuolun;Allegri, Gabriella;Rimann, Nicole;Scherer, Tanja;Willimann, Melanie;Opitz, Lennart;Cunningham, Sharon C.;Alexander, Ian E.;Kipar, Anja;Haeberle, Johannes;Thoeny, Beat;Grisch-Chan, Hiu Man
通讯作者: Grisch-Chan, Hiu Man